C. Packard

J. Danesh, R. Collins, A. Hofman, 2007, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

Effect of Pravastatin on Rate of Kidney Function Loss in People With or at Risk for Coronary Disease

M. Pfeffer, C. Furberg, F. Sacks, 2005, Circulation.

Circulating Interleukin-10 and Risk of Cardiovascular Events: A Prospective Study in the Elderly at Risk

N. Sattar, A. D. de Craen, J. Jukema, 2011, Arteriosclerosis, thrombosis, and vascular biology.

Pharmacological approaches to the modulation of plasma cholesterol.

C. Packard, J. Shepherd, 1988, Trends in pharmacological sciences.

Subpopulations of apolipoprotein A-I in human high-density lipoproteins. Their metabolic properties and response to drug therapy.

C. Packard, J. Shepherd, R. Atmeh, 1983, Biochimica et biophysica acta.

Separating the Mechanism-Based and Off-Target Actions of Cholesteryl Ester Transfer Protein Inhibitors With CETP Gene Polymorphisms

Meena Kumari, Shah Ebrahim, Debbie A Lawlor, 2010, Circulation.

Apolipoproteins: the new prognostic indicator?

C. Packard, 2003 .

The effects of a single nucleotide polymorphism in SLCO1B1 on the pharmacodynamics of pravastatin.

S. Humphries, C. Packard, Kawah Li, 2012, British journal of clinical pharmacology.

The inverse relationship between alanine aminotransferase in the normal range and adverse cardiovascular and non-cardiovascular outcomes.

N. Sattar, A. D. de Craen, R. Westendorp, 2011, International journal of epidemiology.

Improving outcomes through statin therapy - a review of ongoing trials

C. Packard, 2004 .

Cholesterol‐lowering Agents and their Use

C. Packard, J. Shepherd, A. Gaw, 2003 .

Goals of statin therapy: Three viewpoints

N. Stone, C. Packard, G. Thompson, 2002 .

Plasma Leptin and the Risk of Cardiovascular Disease in the West of Scotland Coronary Prevention Study (WOSCOPS)

N. Sattar, C. Packard, A. McMahon, 2001, Circulation.

Lipoprotein-Associated Phospholipase A2as an Independent Predictor of Coronary Heart Disease

G. Lowe, A. Rumley, I. Ford, 2000 .

Lipoprotein-associated phospholipase A(2) as an independent predictor of coronary heart disease

G. Lowe, A. Rumley, I. Ford, 2000 .

Lipid Lowering Therapy in Primary and Secondary Prevention: Insights from LIPID and WOSCOPS

A. Tonkin, B. Strauss, D. Stewart, 1997 .

Plasma triglyceride and low density lipoprotein metabolism

C. Packard, M. Caslake, B. Yip, 1992, European journal of clinical investigation.

Effects of liraglutide on the metabolism of triglyceride‐rich lipoproteins in type 2 diabetes

N. Lundbom, J. Borén, M. Taskinen, 2021, Diabetes, obesity & metabolism.

The end of triglycerides in cardiovascular risk assessment?

C. Packard, J. Petrie, Naveed Satta, 1998, BMJ.

Dietary Fructose and the Metabolic Syndrome

J. Borén, M. Taskinen, C. Packard, 2019, Nutrients.

New metrics needed to visualize the long-term impact of early LDL-C lowering on the cardiovascular disease trajectory.

U. Laufs, W. Weintraub, C. Packard, 2015, Vascular pharmacology.

Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges

U. Laufs, C. Packard, L. Masana, 2021, Heart.

Socioeconomic status and telomere length: the West of Scotland Coronary Prevention Study

N. Samani, I. Ford, C. Packard, 2009, Journal of Epidemiology & Community Health.

Lipid-lowering drug therapies: the evidence

C. Packard, 2000, Proceedings of the Nutrition Society.

Lipoprotein metabolism in the nephrotic syndrome.

C. Packard, G. Warwick, 1993, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation.

C. Packard, M. Caslake, M. McConnell, 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Genetic variation in the interleukin-1 beta-converting enzyme associates with cognitive function. The PROSPER study.

P. Macfarlane, A. D. de Craen, P. Slagboom, 2008, Brain : a journal of neurology.

Potential pathogenic roles of aberrant lipoprotein and fatty acid metabolism in pre‐eclampsia

C. Packard, N. Sattar, I. Greer, 1996, British journal of obstetrics and gynaecology.

Cholesterol feeding increases low density lipoprotein synthesis.

C. Packard, J. Shepherd, K. Carr, 1983, The Journal of clinical investigation.

C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study.

N. Sattar, G. Lowe, J. Norrie, 2002, Diabetes.

SCREENING EXPERIENCE AND BASE-LINE CHARACTERISTICS IN THE WEST OF SCOTLAND CORONARY PREVENTION STUDY

P. Macfarlane, J. Norrie, C. Packard, 1995 .

Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study

P W Macfarlane, S M Cobbe, I Ford, 2001, Circulation.

LDL-Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men with Primary Elevations of LDL-Cholesterol Levels of 190 mg/dL or Above: Analyses from the WOSCOPS 5-year Randomised Trial and 20-year Observational Follow-Up

G. Watts, J. Kastelein, I. Ford, 2017 .

Metabolic syndrome and diabetes mellitus.

P. Macfarlane, N. Sattar, I. Ford, 2004, Circulation.

Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease

C. Packard, 2006, Current opinion in lipidology.

Sodium-lithium countertransport, sodium-hydrogen exchange and membrane microviscosity in patients with hyperlipidaemia.

A. Dominiczak, C. Packard, J. Reid, 1997, Clinical science.

Non-HDL cholesterol as a measure of atherosclerotic risk.

C. Packard, Y. Saito, 2004, Journal of atherosclerosis and thrombosis.

Metabolism of apolipoproteins A‐I and A‐ll and its influence on the high density lipoprotein subfraction distribution in males and females

C. Packard, A. Gotto, J. Shepherd, 1978, European journal of clinical investigation.

The isolation, characterisation and quantification of the equine plasma lipoproteins.

C. Packard, J. Shepherd, T. Watson, 1991, Equine veterinary journal.

Polymorphisms in the gene coding for cholesteryl ester transfer protein are related to plasma high-density lipoprotein cholesterol and transfer protein activity.

C. Packard, D. Freeman, J. Shepherd, 1990, Clinical science.

Thyroid replacement therapy and its influence on postheparin plasma lipases and apolipoprotein-B metabolism in hypothyroidism.

M. Taskinen, C. Packard, J. Shepherd, 1993, The Journal of clinical endocrinology and metabolism.

Leptin Predicts Diabetes but Not Cardiovascular Disease

P. Macfarlane, N. Sattar, A. D. de Craen, 2009, Diabetes Care.

Unpacking and Understanding the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Apolipoprotein B Metabolism

C. Packard, 2017, Circulation.

Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects.

N. Lundbom, J. Borén, M. Taskinen, 2019, Journal of Clinical Lipidology.

Omega-3 fatty acids improve postprandial lipaemia in patients with nephrotic range proteinuria.

S. Bell, C. Packard, J. Cooney, 2009, Atherosclerosis.

Effect of heparin-stimulated plasma lipolytic activity on VLDL APO B subclass metabolism in normal subjects.

M. Taskinen, C. Packard, M. Caslake, 1999, Atherosclerosis.

Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease.

C. Packard, M. Caslake, K. Suckling, 2000, Atherosclerosis.

Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease

C. Packard, M. Caslake, K. Suckling, 2000 .

In vivo metabolism of apo A-I and apo A-II in subjects with apo A-I(Lys107-->0) associated with reduced HDL cholesterol and Lp(AI w AII) deficiency.

M. Taskinen, C. Packard, C. Ehnholm, 1997, Atherosclerosis.

A comparison of two methods to investigate the metabolism of human apolipoproteins A-I and and A-II.

C. Packard, A. Gotto, J. Shepherd, 1978, Journal of lipid research.

Dynamic properties of human high density lipoprotein apoproteins.

C. Packard, A. Gotto, J. Shepherd, 1978, Journal of lipid research.

Probucol reduces plasma lipid peroxides in man.

C. Packard, K. Oldroyd, G. Tait, 1991, Atherosclerosis.

Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans.

J. Borén, A. Palotie, S. Ripatti, 2020, JCI insight.

High density lipoprotein metabolism in the horse (Equus caballus).

C. Packard, D. Freeman, J. Shepherd, 1993, Comparative biochemistry and physiology. B, Comparative biochemistry.

Low density lipoprotein metabolism in a family of familial hypercholesterolemic patients.

H. G. Morgan, C. Packard, J. Shepherd, 1976, Metabolism: clinical and experimental.

Receptor-mediated low density lipoprotein catabolism in man.

C. Packard, J. Shepherd, A. Lorimer, 1979, Journal of lipid research.

Apolipoprotein B overproduction by the perfused liver of the St. Thomas' mixed hyperlipidemic (SMHL) rabbit.

C. Packard, M. Caslake, J. Shepherd, 1999, Journal of lipid research.

Apolipoprotein B metabolism in normal, type IV and type V hyperlipoproteinemic subjects.

C. Packard, A. Gotto, J. Shepherd, 1980, Metabolism: clinical and experimental.

A comparison of two methods to investigate the metabolism of human apolipoproteins A-I and and A-I 1

C. Packard, A. Gotto, J. Shepherd, 2002 .

Accumulation of large very low density lipoprotein in plasma during intravenous infusion of a chylomicron-like triglyceride emulsion reflects competition for a common lipolytic pathway.

A. Hamsten, F. Karpe, C. Packard, 1996, Journal of lipid research.

Development and application of a multicompartmental model to study very low density lipoprotein subfraction metabolism.

C. Packard, J. Shepherd, A. Gaw, 1995, Journal of lipid research.

Metabolism of apoB-100-containing lipoproteins in familial hyperchylomicronemia.

G. Watts, B. Buckley, C. Packard, 1993, Journal of lipid research.

Metabolism of apolipoprotein B-containing lipoproteins in subjects with nephrotic-range proteinuria.

C. Packard, J. Shepherd, T. Demant, 1991, Kidney international.

Influence of apolipoprotein E polymorphism on apolipoprotein B-100 metabolism in normolipemic subjects.

C. Packard, J. Shepherd, T. Demant, 1991, The Journal of clinical investigation.

Comparative cellular uptake and cytotoxicity of a complex of daunomycin-low density lipoprotein in human squamous lung tumour cell monolayers.

D. Kerr, C. Packard, S. Kaye, 1988, Biochemical pharmacology.

Effects of bezafibrate on apolipoprotein B metabolism in type III hyperlipoproteinemic subjects.

C. Packard, J. Shepherd, M. Dominiczak, 1986, Journal of lipid research.

Effects of 1,2-cyclohexanedione modification on the metabolism of very low density lipoprotein apolipoprotein B: potential role of receptors in intermediate density lipoprotein catabolism.

C. Packard, J. Shepherd, R. Clegg, 1985, Journal of lipid research.

Metabolic channelling of apolipoprotein B in very low density lipoprotein.

C. Packard, J. Shepherd, R. Clegg, 1984, Agents and actions. Supplements.

Remodeling of cerebrospinal fluid lipoprotein particles after human traumatic brain injury.

C. Packard, M. Caslake, J. Nicoll, 2003, Journal of neurotrauma.

Two subpopulations of intermediate density lipoprotein and their relationship to plasma triglyceride and cholesterol levels.

C. Packard, M. Caslake, M. McConnell, 1997, Atherosclerosis.

Heterogeneity of apolipoprotein B-100-containing lipoproteins: what we have learnt from kinetic studies.

C. Packard, J. Millar, Chris J. Packard, 1998, Current opinion in lipidology.

Effects of diabetes family history and exercise training on the expression of adiponectin and leptin and their receptors

C. Packard, J. Gill, S. Cleland, 2009, Proceedings of the Nutrition Society.

Identification of a common low density lipoprotein receptor mutation (C163Y) in the west of Scotland.

A. Dominiczak, S. Humphries, A. Dorrance, 1998, Journal of medical genetics.

Effects of bezafibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in type II hyperlipoproteinaemic subjects.

C. Packard, J. Shepherd, A. Lorimer, 1982, Atherosclerosis.

Lipid transport through the plasma: the metabolic basis of hyperlipidaemia.

C. Packard, J. Shepherd, 1987, Bailliere's clinical endocrinology and metabolism.

Apolipoprotein A and B (Sf 100-400) metabolism during bezafibrate therapy in hypertriglyceridemic subjects.

H. G. Morgan, C. Packard, J. Shepherd, 1984, The Journal of clinical investigation.

An investigation of the defect in type III hyperlipoproteinemia using agarose column chromatography.

H. G. Morgan, C. Packard, J. Shepherd, 1978, Clinica chimica acta; international journal of clinical chemistry.

Plasma lipids, lipoproteins and post-heparin lipases in ponies with hyperlipaemia.

C. Packard, J. Shepherd, T. Watson, 1992, Equine veterinary journal.

Very low density and low density lipoprotein subfractions in type III and type IV hyperlipoproteinemia. Chemical and physical properties.

C. Packard, A. Gotto, J. Shepherd, 1979, Biochimica et biophysica acta.

OP-EHEA170733 2546..2550

C. Packard, L. Annemans, K. Ray, 2018 .

Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials.

Marc A Pfeffer, M. Pfeffer, M. Sabatine, 2008, Journal of the American College of Cardiology.

Characterisation of the lipoprotein structure in the St. Thomas' Mixed Hyperlipidaemic (SMHL) rabbit.

C. Packard, M. Caslake, K. Suckling, 2005, Atherosclerosis.

Catabolic rate of low density lipoprotein is influenced by variation in the apolipoprotein B gene.

S. Humphries, R. Houlston, C. Packard, 1988, The Journal of clinical investigation.

Receptors in the Regulation of Cholesterol Metabolism

C. Packard, J. Shepherd, 1989 .

Lipid Metabolism and the Enterohepatic Circulation: The Regulatory Functions of HMG CoA Reductase and Cholesterol 7∝ Hydroxylase

C. Packard, J. Shepherd, 1987 .

Effects of drugs on postprandial lipoprotein metabolism

C. Packard, 1997, Proceedings of the Nutrition Society.

Receptors in the regulation of lipoprotein metabolism.

C. Packard, J. Sheperd, 1988, Annales de biologie clinique.

Pathophysiology of human lipoprotein receptors: clinical consequences of a cellular defect.

C. Packard, J. Shepherd, 1984, Journal of clinical pathology.

Low-density lipoprotein metabolism in mice with soft tissue tumours.

C. McArdle, K. Calman, C. Packard, 1984, Biochimica et biophysica acta.

The Role of Receptors in Apolipoprotein B Metabolism

C. Packard, J. Shepherd, H. R. Slater, 1983 .

Receptor-mediated catabolism and tissue uptake of human low density lipoprotein in the cholesterol-fed, atherosclerotic rabbit.

C. Packard, J. Shepherd, H. R. Slater, 1982, Biochimica et biophysica acta.

Contribution of the Receptor Pathway to Low Density Lipoprotein Catabolism in Humans: New Methods for Quantitation

C. Packard, J. Shepherd, L. McKinney, 1984, Arteriosclerosis.

Receptor-independent low-density lipoprotein catabolism. Evaluation of 2-hydroxyacetaldehyde-treated lipoprotein as a probe for its measurement.

C. Packard, J. Shepherd, L. McKinney, 1984, Biochimica et biophysica acta.

Measurement of receptor-independent lipoprotein catabolism using 1,2 cyclohexanedione-modified low density lipoprotein.

C. Packard, J. Shepherd, H. R. Slater, 1982, Journal of lipid research.

The pathophysiology of cholesterol metabolism in man

C. Packard, J. Shepherd, 1985, Klinische Wochenschrift.

New Perspectives in Human Apolipoprotein B Metabolism

C. Packard, J. Shepherd, 1987 .

Fenofibrate Reduces Low Density Lipoprotein Catabolism in Hypertriglyceridemic Subjects

C. Packard, M. Caslake, J. Shepherd, 1985, Arteriosclerosis.

Abnormal suppression of 3-hydroxy-3-methylglutaryl-CoA reductase activity in cultured human fibroblasts by hypertriglyceridemic very low density lipoprotein subclasses

C. Packard, A. Gotto, J. Shepherd, 1980, Lipids.

Receptor-independent low-density lipoprotein catabolism.

C. Packard, J. Shepherd, 1986, Methods in enzymology.

Effect on saturated and unsaturated fat diets on lipid profiles of plasma lipoproteins.

G. J. Jones, C. Packard, A. Gotto, 1982, Atherosclerosis.

Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy 20-Year Follow-Up of West of Scotland Coronary Prevention Study

I. Ford, C. Packard, C. McCowan, 2016 .

A Comparison of Commercial Kits for the Measurement of Lipoprotein(a)

C. Packard, J. Shepherd, M. Dagen, 1991, Annals of clinical biochemistry.

Regulation of small dense LDL concentration in Korean and Scottish men and women.

Y. Jang, C. Packard, M. Caslake, 2002, Atherosclerosis.

Patients with nephrotic-range proteinuria have apolipoprotein C and E deficient VLDL1.

C. Packard, M. Caslake, M. McConnell, 2000, Kidney international.

Selective measurement of lipoprotein lipase and hepatic triglyceride lipase in heparinized plasma from horses.

C. Packard, J. Shepherd, T. Watson, 1992, American journal of veterinary research.

Ultracentrifugal subfractionation of high-density lipoprotein.

C. Packard, J. Shepherd, D. Bedford, 1984, The Analyst.

Comparative chemistry, pharmacology and mechanism of action of the statins

C. Packard, J. Shepherd, A. Gaw, 1999 .

Apolipoprotein B metabolism in man.

C. Packard, J. Shepherd, 2009, Acta medica Scandinavica. Supplementum.

Metabolism of Human Triglyceride-rich Lipoprotein Remnants

C. Packard, J. Shepherd, R. Clegg, 1986 .

Lipid and lipoprotein concentrations in pregnancies complicated by intrauterine growth restriction.

C. Packard, N. Sattar, J. Shepherd, 1999, The Journal of clinical endocrinology and metabolism.

Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease

C. Packard, M. Caslake, 2003, Current opinion in lipidology.

Effects of dietary monounsaturated fatty acids on lipoprotein concentrations, compositions, and subfraction distributions and on VLDL apolipoprotein B kinetics: dose-dependent effects on LDL.

C. Packard, J. Gill, J. Cooney, 2003, The American journal of clinical nutrition.

Sialic acid-containing components of lipoproteins influence lipoprotein-proteoglycan interactions.

C. Packard, J. Shepherd, J. Millar, 1999, Atherosclerosis.

Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study.

P. Macfarlane, J. Kennedy, J. Norrie, 1997, European heart journal.

Low-density lipoprotein metabolism in the nephrotic syndrome.

C. Packard, M. Caslake, J. Shepherd, 1990, Metabolism: clinical and experimental.

Effects of cholestyramine on receptor-mediated plasma clearance and tissue uptake of human low density lipoproteins in the rabbit.

C. Packard, J. Shepherd, S. Bicker, 1980, The Journal of biological chemistry.

Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia

J. Borén, M. Taskinen, C. Packard, 2022, Nature Reviews Cardiology.

Haemochromatosis gene mutations and risk of coronary heart disease: a west of Scotland coronary prevention study (WOSCOPS) substudy

C. Packard, A. McMahon, D. Gaffney, 2004, Heart.

Fractionation of cholesteryl ester rich intermediate density lipoprotein subpopulations by chondroitin sulphate.

C. Packard, L. Duvillard, M. Caslake, 2007, Atherosclerosis.

Effects of short-term detraining on postprandial metabolism, endothelial function, and inflammation in endurance-trained men: dissociation between changes in triglyceride metabolism and endothelial function

W. Ferrell, F. Tsofliou, C. Packard, 2003 .

Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target

C. Packard, 2009, Current opinion in cardiology.

Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity

Marcelo P. Segura-Lepe, A. J. Slater, Dajiang J. Liu, 2018, Nature Genetics.

Influence of etofibrate on low density lipoprotein metabolism.

C. Packard, M. Caslake, J. Shepherd, 1988, Atherosclerosis.

Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension

He Zhang, Andres Metspalu, Fotios Drenos, 2016, Nature Genetics.

11 – Low Density Lipoprotein Receptor Activity in Man

C. Packard, J. Shepherd, H. R. Slater, 1982 .

C-Reactive Protein and Prediction of Coronary Heart Disease and Global Vascular Events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) Epidemiology

P. Macfarlane, N. Sattar, R. Westendorp, 2007 .

Lipoprotein Subfraction Concentrations in Preeclampsia: Pathogenic Parallels to Atherosclerosis

C. Packard, N. Sattar, J. Shepherd, 1997, Obstetrics and gynecology.

Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials

Barry J. Davis, M. Landray, R. Collins, 2022, The Lancet.

Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity

Marcelo P. Segura-Lepe, A. J. Slater, Dajiang J. Liu, 2019, Nature Genetics.

Pharmacological modification of lipoprotein metabolism.

C. Packard, J. Shepherd, 1987, Biochemical Society transactions.

The Xba1 polymorphism of the apolipoprotein B gene influences the degradation of low density lipoprotein in vitro.

C. Packard, M. Caslake, J. Shepherd, 1989, Biochimica et biophysica acta.

Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100- and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes.

F. Kronenberg, N. Lundbom, J. Borén, 2020, Arteriosclerosis, thrombosis, and vascular biology.

Smoking and plasma lipoprotein metabolism.

C. Packard, D. Freeman, Dilys J. Freeman, 1995, Clinical science.

Postprandial metabolism of apolipoproteins B48, B100, C-III, and E in humans with APOC3 loss-of-function mutations

M. Laakso, J. Borén, S. Ripatti, 2022, JCI insight.

CCR2 and coronary artery disease: a woscops substudy

I. Gray, C. Packard, A. McMahon, 2010, BMC Research Notes.

Iatrogenic profound hypoalphalipoproteinaemia: an unrecognised cause of very low HDL cholesterol.

C. Packard, M. Murphy, D. O'reilly, 1995, Postgraduate medical journal.

Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease

Deepak L. Bhatt, J. Danesh, A. Wood, 2019, JAMA.

Triglyceride lowering 2.0: back to the future?

C. Packard, 2019, European heart journal.

Insulin resistance in the St. Thomas' mixed hyperlipidaemic (SMHL) rabbit, a model for familial combined hyperlipidaemia.

C. Packard, M. Caslake, K. Suckling, 2000, Atherosclerosis.

Effects of nicotinic acid therapy on high-density lipoprotein metabolism in type II and type IV hyperlipoproteinaemia.

H. G. Morgan, C. Packard, J. Shepherd, 1980, Biochimica et biophysica acta.

A Longitudinal Study of the Relationships between Haemostatic, Lipid, and Oestradiol Changes during Normal Human Pregnancy

A. Rumley, C. Packard, N. Sattar, 1999, Thrombosis and Haemostasis.

Effect of saturated and unsaturated fat diets on molecular species of phosphatidylcholine and sphingomyelin of human plasma lipoproteins.

C. Packard, A. Gotto, A. Kuksis, 1981, Biochimica et biophysica acta.

Metabolic Basis of the Atherogenic Lipoprotein Phenotype

C. Packard, J. Shepherd, 1995 .

Prospective pravastatin pooling project: Relative risk reduction by baseline HDL and TG concentrations

A. Keech, E. Braunwald, C. Furberg, 2000 .

Abstract 814: CRP and Risk of Vascular Events in PROSPER

P. Macfarlane, N. Sattar, R. Westendorp, 2006 .

C-reactive protein is an independent predictor of risk for the development of diabetes mellitus in the West of Scotland Coronary Prevention Study

N. Sattar, G. Lowe, J. Norrie, 2002 .

FRI0134 Interleukin-6 Blockade Raises LDL via Reduced Catabolism Rather than via Increased Synthesis – A Cytokine-Specific Mechanism for Cholesterol Changes in Rheumatoid Arthritis

C. Packard, I. McInnes, N. Sattar, 2016 .

Remodelling of cerebrospinal fluid lipoproteins after subarachnoid hemorrhage.

C. Packard, M. Caslake, J. Nicoll, 2003, Atherosclerosis.

C-reactive protein, fibrinogen, and cardiovascular disease prediction.

J. Gallacher, J. Danesh, A. Hofman, 2012, The New England journal of medicine.

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

P. Macfarlane, I. Ford, C. Packard, 1995, The New England journal of medicine.

Effects of pregnancy and lactation on plasma lipid and lipoprotein concentrations, lipoprotein composition and post-heparin lipase activities in Shetland pony mares.

C. Packard, J. Shepherd, T. Watson, 1993, Journal of reproduction and fertility.

Increased atherogenicity of low-density lipoprotein in heavy proteinuria.

C. Packard, M. Caslake, M. McConnell, 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Electrophoretic mobility in agarose of very low density lipoprotein subfractions in type III hyperlipoproteinaemia.

C. Packard, D. Ballantyne, D. Bedford, 1977, Clinica chimica acta; international journal of clinical chemistry.

Hepatitis C virus and atherosclerosis: A legacy after virologic cure?

C. Packard, M. Bassendine, R. Neely, 2017, Clinics and research in hepatology and gastroenterology.

Deceptive hyperbilirubinaemia in a newborn with familial lipoprotein lipase deficiency

C. Packard, T. Fok, L. Chan, 2001, Journal of paediatrics and child health.

Measurement and physiological significance of lipoprotein and hepatic lipase activities in preheparin plasma.

C. Packard, S. Clegg, T. Watson, 1995, Clinical chemistry.

Lipoprotein (a) levels in normal pregnancy and in pregnancy complicated with pre-eclampsia.

C. Packard, N. Sattar, J. Shepherd, 2000, Atherosclerosis.

Effect of combined therapy with bezafibrate and cholestyramine on low-density lipoprotein metabolism in type IIa hypercholesterolemia.

C. Packard, M. Caslake, J. Shepherd, 1989, Metabolism: clinical and experimental.

Influence of polymorphism Q3405E and mutation A3371V in the apolipoprotein B gene on LDL receptor binding.

C. Packard, D. Gaffney, M. Hoffs, 1998, Atherosclerosis.

Genetics, Drugs and Low Density Lipoprotein Metabolism

C. Packard, J. Shepherd, 1989 .

Metabolic heterogeneity in very low-density lipoproteins.

C. Packard, J. Shepherd, 1987, American heart journal.

Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis

N. Sattar, C. Packard, I. McInnes, 2016, Annals of the rheumatic diseases.

Genetic and environmental modulation of low-density lipoprotein catabolism.

C. Packard, B. Griffin, M. Caslake, 1990, Biochemical Society transactions.

Serial Metabolic Measurements and Conversion to Type 2 Diabetes in the West of Scotland Coronary Prevention Study

N. Forouhi, I. Ford, C. Packard, 2007, Diabetes.

Major statin trials : relationship between lipid changes and cardiovascular events

C. Packard, 1999 .

HIGH DENSITY LIPOPROTEIN: GUARDIAN OF THE VASCULAR SYSTEM?

C. Packard, R. Hobbs, A. Nunn, 2002, International journal of clinical practice.

Atherogenicity of Triglyceride-Rich Lipoproteins: Clinical Aspects

C. Packard, B. Griffin, M. Caslake, 1993 .

Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease.

Deepak L. Bhatt, J. Danesh, M. Sabatine, 2019, JAMA.

Overproduction of small very low density lipoproteins (Sf 20-60) in moderate hypercholesterolemia: relationships between apolipoprotein B kinetics and plasma lipoproteins.

C. Packard, B. Griffin, M. Caslake, 1995, Journal of lipid research.

Metabolism of VLDL and LDL subclasses.

C. Packard, B. Griffin, 1994, Current opinion in lipidology.

Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group.

G. Lowe, A. Rumley, I. Ford, 2000, The New England journal of medicine.

Reduced Glomerular Filtration Rate and Its Association with Clinical Outcome in Older Patients at Risk of Vascular Events: Secondary Analysis

N. Sattar, A. D. de Craen, J. Jukema, 2009, PLoS medicine.

An Overview of Lipoprotein Metabolism

C. Packard, J. Shepherd, 1987 .

Effects of PNPLA3 I148M on hepatic lipid and very‐low‐density lipoprotein metabolism in humans

J. Borén, A. Palotie, S. Ripatti, 2021, Journal of internal medicine.

Effect of simvastatin on plasma lipid and lipoprotein concentrations and low-density lipoprotein metabolism in the nephrotic syndrome.

C. Packard, J. Shepherd, D. Grierson, 1992, Clinical science.

Interleukin-6, Fibrin D-Dimer, and Coagulation Factors VII and XIIa in Prediction of Coronary Heart Disease

G. Lowe, A. Rumley, I. Ford, 2004, Arteriosclerosis, thrombosis, and vascular biology.

The reticuloendothelial system and low density lipoprotein metabolism in the rabbit.

C. Packard, J. Shepherd, H. R. Slater, 1982, Biochimica et biophysica acta.

Effects of Lipid-Lowering Drugs on High Density Lipoprotein Structure and Metabolism

C. Packard, J. Shepherd, 1987 .

Effects of prior moderate exercise on postprandial metabolism and vascular function in lean and centrally obese men.

W. Ferrell, C. Packard, J. Gill, 2004, Journal of the American College of Cardiology.

Socioeconomic Status and the Cerebellar Grey Matter Volume. Data from a Well-Characterised Population Sample

N. Sattar, I. Ford, C. Packard, 2013, The Cerebellum.

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

Yasuo Ohashi, Paul Welsh, Luigi Tavazzi, 2010, The Lancet.

Statins : The HMG CoA reductase inhibitors in perspective

C. Packard, J. Shepherd, A. Gaw, 2003 .

The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans

J. Borén, M. Taskinen, C. Packard, 2020, Frontiers in Endocrinology.

Emerging Therapeutic Approaches to Treat Dyslipidemia

C. Packard, D. Preiss, 2014, Current Cardiology Reports.

Genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease

Sara M. Willems, Audrey Y. Chu, Daniel F. Freitag, 2016 .

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential

P. Libby, P. Ridker, J. Després, 2019, Cardiovascular Diabetology.

Plasma lipid transport in the horse (Equus caballus).

C. Packard, J. Shepherd, T. Watson, 1993, Comparative biochemistry and physiology. B, Comparative biochemistry.

Inheritance of coronary artery disease in men: an analysis of the role of the Y chromosome

Nilesh J Samani, Panos Deloukas, Jeanette Erdmann, 2012, The Lancet.

Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trial

J. Jukema, A. Lichtenstein, J. Jukema, 2010, Journal of Lipid Research.

Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER.

J. Ordovás, A. D. de Craen, J. Jukema, 2008, Atherosclerosis.

Effect of cholestyramine on low-density lipoproteins.

H. G. Morgan, C. Packard, J. Shepherd, 1980, New England Journal of Medicine.

Discovery of rare variants associated with blood pressure regulation through meta-analysis of 1.3 million individuals

Tom R. Gaunt, James M. Eales, Dajiang J. Liu, 2020, Nature Genetics.

Discovery of rare variants associated with blood pressure regulation through meta-analysis of 1.3 million individuals

James M. Eales, Dajiang J. Liu, Yan V. Sun, 2020, Nature Genetics.

Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity

Marcelo P. Segura-Lepe, A. J. Slater, Dajiang J. Liu, 2017, Nature Genetics.

Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies

P. Macfarlane, P. Whincup, A. D. de Craen, 2008, The Lancet.

Major lipids, apolipoproteins, and risk of vascular disease.

J. Danesh, R. Collins, A. Wood, 2009, JAMA.

Independent mutations at codon 3500 of the apolipoprotein B gene are associated with hyperlipidemia.

K. Vass, C. Packard, M. Caslake, 1995, Arteriosclerosis, thrombosis, and vascular biology.

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

Lale Tokgözoğlu, Ian Graham, Stephen J. Nicholls, 2017, European heart journal.

Genome of the Netherlands population-specific imputations identify an ABCA6 variant associated with cholesterol levels

Pieter B. T. Neerincx, O. Franco, A. Hofman, 2015, Nature communications.

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel

R. Krauss, J. Borén, H. Schunkert, 2020, European heart journal.

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials

John Fuller, Luigi Tavazzi, John Wikstrand, 2019, The Lancet.

Modelling total coronary heart disease burden and long-term benefit of cholesterol lowering in middle aged men with and without a history of cardiovascular disease

I. Ford, C. Packard, R. Young, 2017, European heart journal. Quality of care & clinical outcomes.

Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study

I. Ford, C. Packard, A. McConnachie, 2013, European heart journal.

J. Gallacher, J. Danesh, A. Hofman, 2012, JAMA.

Effect of pravastatin in people with diabetes and chronic kidney disease.

M. Pfeffer, A. Keech, C. Furberg, 2005, Journal of the American Society of Nephrology : JASN.

Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and

G. Watts, J. Kastelein, I. Ford, 2017, Circulation.

Exome Chip Meta-analysis Fine Maps Causal Variants and Elucidates the Genetic Architecture of Rare Coding Variants in Smoking and Alcohol Use

Dajiang J. Liu, J. Danesh, R. Marioni, 2019, Biological Psychiatry.

Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels

C. Packard, S. Marcovina, 2006, Journal of internal medicine.

Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty‐person/ten‐country panel

R. Krauss, S. Humphries, C. Furberg, 2006, Journal of internal medicine.

Current Controlled Trials in Cardiovascular Medicine a Prospective Study of Pravastatin in the Elderly at Risk (prosper): Screening Experience and Baseline Characteristics

John Norrie, J Wouter Jukema, Gerard Jan Blauw, 2002 .

Are Markers of Inflammation More Strongly Associated with Risk for Fatal Than for Nonfatal Vascular Events?

P. Macfarlane, A. D. de Craen, J. Jukema, 2009, PLoS medicine.

Early life socioeconomic status, chronic physiological stress and hippocampal N-acetyl aspartate concentrations

Donald M. Hadley, Jonathan Cavanagh, Alex McConnachie, 2012, Behavioural Brain Research.

Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study

N. Samani, J. Thompson, I. Ford, 2007, The Lancet.

Familial combined hyperlipidaemia linked to the apolipoprotein AI–CIII–AIV gene cluster on chromosome 11q23q–q24

M. Farrall, P. Cullen, C. Packard, 1991, Nature.

Consumption of Fish Oil Providing Amounts of Eicosapentaenoic Acid and Docosahexaenoic Acid That Can Be Obtained from the Diet Reduces Blood Pressure in Adults with Systolic Hypertension: A Retrospective Analysis.

P. Calder, A. Minihane, Christine M. Williams, 2016, The Journal of nutrition.

Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis

James R. Staley, Daniel F. Freitag, J. Danesh, 2018, JAMA cardiology.

Unraveling the directional link between adiposity and inflammation: a bidirectional Mendelian randomization approach.

J Wouter Jukema, Peter W Macfarlane, Naveed Sattar, 2009, The Journal of clinical endocrinology and metabolism.

Overproduction of VLDL1 Driven by Hyperglycemia Is a Dominant Feature of Diabetic Dyslipidemia

Bernt Wennberg, Martin Adiels, Jukka Westerbacka, 2005, Arteriosclerosis, thrombosis, and vascular biology.

Action of danazol on plasma lipids and lipoprotein metabolism.

C. Packard, J. Shepherd, 1994, Acta obstetricia et gynecologica Scandinavica. Supplement.

Prospective analysis of the association of infection with CagA bearing strains of Helicobacter pylori and coronary heart disease

N. Samani, C. Packard, A. McMahon, 2002, Heart.

West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials

P. Macfarlane, J. Kennedy, J. Norrie, 1996 .

Genetic invalidation of Lp-PLA2 as a therapeutic target: Large-scale study of five functional Lp-PLA2-lowering alleles

James R. Staley, Daniel F. Freitag, Dermot F. Reilly, 2016, European journal of preventive cardiology.

Differences in atherosclerosis according to area level socioeconomic deprivation: cross sectional, population based study

N. Sattar, I. Ford, C. Packard, 2009, BMJ : British Medical Journal.

Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib

M. Pfeffer, F. Sacks, J. Tardif, 2021, Circulation. Genomic and precision medicine.

Effect of Pravastatin on Coronary Disease Events in Subgroups Defined by Coronary Risk Factors: The Prospective Pravastatin Pooling Project

A. Keech, E. Braunwald, C. Furberg, 2000, Circulation.

Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies

J. Danesh, R. Collins, A. Hofman, 2010, The Lancet.

Long-term follow-up of lipid-lowering trials

I. Ford, C. Packard, 2015, Current opinion in lipidology.

Understanding IMPROVE-IT and the cardinal role of LDL-C lowering in CVD prevention.

U. Laufs, C. Packard, O. Descamps, 2014, European heart journal.

Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy

I. Ford, C. Packard, C. McCowan, 2016, Circulation.

Long-Term Effects of Statin Treatment in Elderly People: Extended Follow-Up of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)

H. Comber, N. Sattar, A. D. de Craen, 2013, PloS one.

High-Sensitivity Cardiac Troponin, Statin Therapy, and Risk of Coronary Heart Disease

D. Newby, I. Ford, C. Packard, 2016, Journal of the American College of Cardiology.

Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS).

P. Macfarlane, J. Norrie, C. Packard, 1998, Circulation.

Activation of Hemostasis and Decline in Cognitive Function in Older People

N. Sattar, A. D. de Craen, J. Jukema, 2010, Arteriosclerosis, Thrombosis and Vascular Biology.

Accelerated Telomere Attrition Is Associated with Relative Household Income, Diet and Inflammation in the pSoBid Cohort

Paul C. D. Johnson, N. Sattar, I. Ford, 2011, PloS one.

Plasma C reactive protein concentration indicates a direct relation between systemic inflammation and social deprivation

G. Watt, J. Norrie, C. Packard, 2005, Heart.

Metabolism of apolipoprotein B in large triglyceride-rich very low density lipoproteins of normal and hypertriglyceridemic subjects.

C. Packard, A. Gotto, J. Shepherd, 1984, The Journal of clinical investigation.

CD36 and SR-BI are involved in cellular uptake of provitamin A carotenoids by Caco-2 and HEK cells, and some of their genetic variants are associated with plasma concentrations of these micronutrients in humans.

P. Calder, A. Minihane, P. Galan, 2013, The Journal of nutrition.

CD 36 and SR-BI Are Involved in Cellular Uptake of Provitamin A Carotenoids by Caco-2 and HEK Cells , and Some of Their Genetic Variants Are Associated with Plasma Concentrations of These Micronutrients in Humans 1 – 3

P. Calder, A. Minihane, P. Galan, 2013 .

Sensitive methods to study human apolipoprotein B metabolism using stable isotope-labeled amino acids.

J Shepherd, C. Packard, J. Shepherd, 1996, The American journal of physiology.

Causes and Consequences of Hypertriglyceridemia

J. Borén, M. Taskinen, C. Packard, 2020, Frontiers in Endocrinology.

Investigation of human apoB48 metabolism using a new, integrated non‐steady‐state model of apoB48 and apoB100 kinetics

J. Borén, M. Taskinen, H. Zhou, 2019, Journal of internal medicine.

A new combined multicompartmental model for apolipoprotein B-100 and triglyceride metabolism in VLDL subfractions Published, JLR Papers in Press, October 16, 2004. DOI 10.1194/jlr.M400108-JLR200

Bernt Wennberg, Martin Adiels, Jukka Westerbacka, 2005, Journal of Lipid Research.

Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates.

Dorothy Bedford, C. Packard, M. Caslake, 2002, Atherosclerosis.

Supraphysiological concentrations of estradiol in menopausal women given repeated implant therapy do not adversely affect lipid profiles.

C. Packard, N. Sattar, I. Greer, 2002, Human reproduction.

Pravastatin and cognitive function in the elderly. Results of the PROSPER study

P. Macfarlane, J. Jolles, N. Sattar, 2009, Journal of Neurology.

A polymorphism of the cholesteryl ester transfer protein gene predicts cardiovascular events in non-smokers in the West of Scotland Coronary Prevention Study.

N. Samani, P. Braund, Suzanne Cheng, 2003, European heart journal.

Cardio-metabolic risk factors and cortical thickness in a neurologically healthy male population: Results from the psychological, social and biological determinants of ill health (pSoBid) study☆☆☆

Jonathan Cavanagh, Alex McConnachie, Rajeev Krishnadas, 2013, NeuroImage: Clinical.

Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke

C. Packard, M. Caslake, 2005, Nature Clinical Practice Cardiovascular Medicine.

Effect of Insulin Therapy on Metabolic Fate of Apolipoprotein B–Containing Lipoproteins in NIDDM

M. Taskinen, C. Packard, J. Shepherd, 1990, Diabetes.

High Density Lipoprotein pathway as a therapeutic target for coronary heart disease: individual participant meta-analysis in 28,597 individuals with 4197 coronary events

V. Salomaa, A. Hingorani, N. Sattar, 2020, medRxiv.

At what level of coronary heart disease risk should a statin be prescribed?

C. Packard, A. Gaw, 2000, Current opinion in lipidology.

Lipoprotein (a), cholesterol and triglycerides in women with venous thromboembolism.

C. Packard, R. Tait, N. Sattar, 2000, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Testing cognitive function in elderly populations: the PROSPER study

P. Macfarlane, E. Bollen, R. Westendorp, 2002, Journal of neurology, neurosurgery, and psychiatry.

Determinants of Achieved LDL Cholesterol and “Non-HDL” Cholesterol in the Management of Dyslipidemias

C. Packard, 2018, Current Cardiology Reports.

Plasma apolipoprotein-B is an important risk factor for cardiovascular disease, and its assessment should be routine clinical practice.

J. Jukema, S. Trompet, C. Packard, 2018, Current opinion in lipidology.

LDL cholesterol: How low to go?

C. Packard, 2017, Trends in cardiovascular medicine.

Optimizing lipid-lowering therapy in the prevention of coronary heart disease

C. Packard, 2010, Expert review of clinical pharmacology.

Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderly[S]

A. D. de Craen, R. Hegele, R. Westendorp, 2010, Journal of Lipid Research.

An increased incidence of apolipoprotein E2/E2 and E4/E4 in retinitis pigmentosa

Carolyn A. Converse, C. Packard, J. Shepherd, 1993, Lipids.

A triumvirate of targets in the prevention and treatment paradigm for cardiovascular disease.

C. Packard, 2006, Atherosclerosis. Supplements.

Is cholesterol the major lipoprotein risk factor in coronary heart disease?--a Franco-Scottish overview.

C. Packard, J. Fruchart, C. J. Packard, 1997, Current medical research and opinion.

Personality, Socio-Economic Status and Inflammation: Cross-Sectional, Population-Based Study

N. Sattar, I. Ford, C. Packard, 2013, PloS one.

Soluble ST2 Associates with Diabetes but Not Established Cardiovascular Risk Factors: A New Inflammatory Pathway of Relevance to Diabetes?

N. Sattar, I. Ford, C. Packard, 2012, PloS one.

Dementia and statins

G. Lowe, A. Rumley, C. Packard, 2001, The Lancet.

Blood Rheology, Cardiovascular Risk Factors, and Cardiovascular Disease: The West of Scotland Coronary Prevention Study

A. Rumley, J. Norrie, I. Ford, 2000, Thrombosis and Haemostasis.

The effects of cholestyramine on high density lipoprotein metabolism.

H. G. Morgan, C. Packard, J. Shepherd, 1979, Atherosclerosis.

Effects of Dietary-Fat Saturation on the Composition of Very-Low-Density Lipoproteins and on the Metabolism of their Major Apoprotein, Apolipoprotein B

C. Packard, J. Shepherd, D. Taunton, 1978 .

25-Hydroxyvitamin D is lower in deprived groups, but is not associated with carotid intima media thickness or plaques: results from pSoBid.

I. Ford, C. Packard, A. McConnachie, 2012, Atherosclerosis.

Abdominal obesity, impaired nonesterified fatty acid suppression, and insulin-mediated glucose disposal are early metabolic abnormalities in families with premature myocardial infarction.

J. Kooner, T. Aitman, C. Packard, 1998, Arteriosclerosis, thrombosis, and vascular biology.

Association Between ADAMTS1 Matrix Metalloproteinase Gene Variation, Coronary Heart Disease, and Benefit of Statin Therapy

M. Pfeffer, M. Sabatine, E. Braunwald, 2008, Arteriosclerosis, thrombosis, and vascular biology.

The Microsomal Triglyceride Transfer Protein Gene-493T Variant Lowers Cholesterol But Increases the Risk of Coronary Heart Disease

P. Macfarlane, F. Karpe, M. Neville, 2004, Circulation.

Atherogenic lipoprotein phenotype in Type 2 diabetes: reversal with micronised fenofibrate

C. Packard, M. Caslake, M. Feher, 1999, Diabetes/metabolism research and reviews.

Contribution of apolipoprotein E genotype and docosahexaenoic acid to the LDL-cholesterol response to fish oil.

A. Minihane, Christine M. Williams, C. Packard, 2010, Atherosclerosis.

ABCA1 gene variation and heart disease risk reduction in the elderly during pravastatin treatment.

A. D. de Craen, J. Jukema, E. Schaefer, 2014, Atherosclerosis.

Genetic variation at the SLCO1B1 gene locus and low density lipoprotein cholesterol lowering response to pravastatin in the elderly.

A. D. de Craen, R. Westendorp, J. Jukema, 2011, Atherosclerosis.

KIF6, LPA, TAS2R50, and VAMP8 genetic variation, low density lipoprotein cholesterol lowering response to pravastatin, and heart disease risk reduction in the elderly.

A. D. de Craen, J. Jukema, R. Westendorp, 2011, Atherosclerosis.

Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population.

J. Ordovás, A. D. de Craen, J. Jukema, 2008, Atherosclerosis.

Association of oily fish intake, sex, age, BMI and APOE genotype with plasma long-chain n-3 fatty acid composition

P. Calder, A. Minihane, J. Mathers, 2018, British Journal of Nutrition.

Atherogenic lipid profile in elderly patients with ischaemic cerebrovascular disease

D. Stott, C. Packard, C. Vergani, 2000, The Lancet.

In vivo studies of VLDL metabolism and LDL heterogeneity.

C. Packard, T. Demant, 1998, European heart journal.

Receptor-independent catabolism of low density lipoprotein. Involvement of the reticuloendothelial system.

C. Packard, J. Shepherd, H. R. Slater, 1982, The Journal of biological chemistry.

Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life

Jennifer G. Robinson, Neha J. Pagidipati, M. Pencina, 2018, Journal of the American Heart Association.

UK Food Standards Agency cis-monounsaturated fatty acid workshop report.

Christine M. Williams, T. Sanders, C. Packard, 2002, The British journal of nutrition.

Genome-Wide Study of Gene Variants Associated with Differential Cardiovascular Event Reduction by Pravastatin Therapy

N. Sattar, J. Catanese, F. Sacks, 2012, PloS one.

Lipid-modifying effects of rosuvastatin in postmenopausal women with hypercholesterolemia who are receiving hormone replacement therapy*

C. Packard, E. Stein, J. Shepherd, 2004, Current medical research and opinion.

Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial.

R. Holman, J. McMurray, N. Sattar, 2014, The lancet. Diabetes & endocrinology.

SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe.

J. Danesh, A. Peters, R. Kronmal, 2021, European heart journal.

Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk.

C. Packard, B. Griffin, M. Caslake, 1994, Atherosclerosis.

Beyond statins: what to expect from add-on lipid regulating therapy?

U. Laufs, W. Weintraub, C. Packard, 2013, European heart journal.

The atherogenic lipoprotein phenotype: small dense LDL and lipoprotein remnants in nephrotic range proteinuria.

C. Packard, M. Caslake, M. McConnell, 2001, Atherosclerosis.

Strategies to alter the trajectory of atherosclerotic cardiovascular disease.

C. Packard, 2019, Current opinion in lipidology.

Exercise training has greater effects on insulin sensitivity in daughters of patients with type 2 diabetes than in women with no family history of diabetes

C. Packard, J. Gill, S. Cleland, 2008, Diabetologia.

Goals of statin therapy: three viewpoints.

N. Stone, C. Packard, G. Thompson, 2004, Current atherosclerosis reports.

Obesity is associated with fatal coronary heart disease independently of traditional risk factors and deprivation

Peter Macfarlane, Naveed Sattar, P. Macfarlane, 2011, Heart.

Intravascular transfer contributes to postprandial increase in numbers of very-low-density hepatitis C virus particles.

C. Packard, J. McLauchlan, M. Caslake, 2010, Gastroenterology.

Hepatic production of VLDL1 but not VLDL2 is related to insulin resistance in normoglycaemic middle-aged subjects.

C. Packard, J. Gill, J. Cooney, 2004, Atherosclerosis.

Familial hypobetalipoproteinemia due to a novel early stop mutation.

R. Hegele, C. Packard, M. Caslake, 2008, Journal of Clinical Lipidology.

Studies of apolipoprotein B-100 metabolism using radiotracers and stable isotopes

C. Packard, T. Demant, 1997, European Journal of Pediatrics.

N-terminal pro-B-type natriuretic peptide and the prediction of primary cardiovascular events: results from 15-year follow-up of WOSCOPS

V. Gudnason, P. Macfarlane, N. Sattar, 2012, European heart journal.

Blood Pressure Variability and Cardiovascular Risk in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)

J. Wouter Jukema, A. D. de Craen, J. Jukema, 2012, PloS one.

Sensitive Mass Spectrometry Techniques for Measuring Metabolism of Human Apolipoprotein B In Vivo

C. Packard, J. Shepherd, T. Demant, 1994 .

The apolipoprotein B R3531C mutation. Characteristics of 24 subjects from 9 kindreds.

V. Schumaker, C. Packard, M. Malloy, 1999, Journal of lipid research.

Collaborative pooled analysis of data on C-reactive protein gene variants and coronary disease: judging causality by Mendelian randomisation

Jack Bowden, Alex P. Reiner, Meena Kumari, 2008 .

Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein.

C. Packard, C J Packard, 2003, Biochemical Society transactions.

Chapter 3. Lipoprotein Metabolism

C. Packard, J. Shepherd, 1989 .

Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage

I. Ford, C. Packard, A. McConnachie, 2014 .

Early life socioeconomic adversity is associated in adult life with chronic inflammation, carotid atherosclerosis, poorer lung function and decreased cognitive performance: a cross-sectional, population-based study

Jonathan Cavanagh, Carol Tannahill, Vladimir Bezlyak, 2011, BMC public health.

The envirome and the connectome: exploring the structural noise in the human brain associated with socioeconomic deprivation

Jonathan Cavanagh, Rajeev Krishnadas, Jongrae Kim, 2013, Front. Hum. Neurosci..

Genetic Variants Related to Combined Exposure to both Lower Low- Density Lipoproteins and Lower Systolic Blood Pressure with Lifetime Risk of Cardiovascular Disease. JAMA Network Open, E1-E11

Deepak L. Bhatt, J. Danesh, M. Sabatine, 2019 .

Combined Exposure to both Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure with Lifetime Risk of Cardiovascular Disease. JAMA

J. Danesh, M. Sabatine, U. Laufs, 2019 .

Unraveling the Directional Link between Adiposity and Inflammation: A Bidirectional Mendelian Randomization Approach.

P. Macfarlane, A. Hingorani, N. Sattar, 2009, Endocrine reviews.

A monoclonal-antibody-based immunoradiometric assay for apoprotein B in low-density lipoprotein.

C. Packard, J. Shepherd, R. Tindle, 1985, Clinical chemistry.

Diagnosis of type III hyperlipoproteinemia by chromatography of plasma lipoproteins on columns containing agarose.

C. Packard, J. Shepherd, F. Dryburgh, 1975, Clinical chemistry.

Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study.

P. Macfarlane, N. Sattar, I. Ford, 2004, Diabetes.

New dimension of statin action on apoB atherogenicity

C. Packard, M. Caslake, M. Chapman, 2003, Clinical cardiology.

Novel antecedent plasma biomarkers of cardiovascular disease: improved evaluation methods and comparator benchmarks raise the bar

N. Sattar, C. Packard, P. Welsh, 2008, Current opinion in lipidology.

Peroxisome proliferator activated receptor delta genotype in relation to cardiovascular risk factors and risk of coronary heart disease in hypercholesterolaemic men

A. Hamsten, F. Karpe, C. Packard, 2003, Journal of internal medicine.

A middle-aged woman, being treated for hypercholesterolaemia, presents with abnormal liver function

C. Packard, A. Williams, R. Finnie, 1999 .

Relationship between circulating microRNA-30c with total- and LDL-cholesterol, their circulatory transportation and effect of statins.

C. Packard, M. Caslake, L. Denby, 2017, Clinica chimica acta; international journal of clinical chemistry.

Association of oily ﬁ sh intake, sex, age, BMI and APOE genotype with plasma long-chain n-3 fatty acid composition

P. Calder, A. Minihane, C. Packard, 2018 .

Investigation of human apoB48 metabolism using a new, integrated non‐steady‐state model of apoB48 and apoB100 kinetics

J. Borén, M. Taskinen, C. Packard, 2019, Journal of internal medicine.

Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity

Marcelo P. Segura-Lepe, A. J. Slater, Dajiang J. Liu, 2018, Nature Genetics.

Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters

C. Packard, N. Sattar, I. Greer, 2001, Clinical endocrinology.

Socioeconomic Deprivation and Cortical Morphology: Psychological, Social, and Biological Determinants of Ill Health Study

N. Sattar, I. Ford, C. Packard, 2013, Psychosomatic medicine.

Apolipoprotein E genotype and the cardiovascular disease risk phenotype: impact of sex and adiposity (the FINGEN study).

P. Calder, A. Minihane, J. Mathers, 2012, Atherosclerosis.

Interaction of personality traits with social deprivation in determining mental wellbeing and health behaviours.

N. Sattar, C. Packard, A. McConnachie, 2012, Journal of public health.

Cardiovascular risk factors and LDL subfraction profile in Type 2 diabetes mellitus subjects with good glycaemic control.

E. Tai, C. Packard, S. C. Lim, 2001, Diabetes research and clinical practice.

Lipoprotein metabolism in lipase deficient states: studies in primary and secondary hyperlipidaemia.

C. Packard, J. Shepherd, 1993, Biochemical Society transactions.

Asp92Asn Polymorphism in the Myeloid IgA Fc Receptor Is Associated With Myocardial Infarction in Two Disparate Populations: CARE and WOSCOPS

M. Sabatine, J. Catanese, F. Sacks, 2006, Arteriosclerosis, thrombosis, and vascular biology.

Overview of fenofibrate.

C. Packard, 1998, European heart journal.

Low-density lipoprotein receptor pathway in man: its role in regulating plasma low-density lipoprotein levels

C. Packard, J. Shepherd, 1983 .

3P-0786 Rosuvastatin: Kinetics of apoB-containing lipoproteins in moderate hypercholesterolemia

C. Packard, M. Caslake, N. Joss, 2003 .

Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity

Marcelo P. Segura-Lepe, A. J. Slater, Dajiang J. Liu, 2019, Nature Genetics.

Biogerontology: Mechanisms and Interventions

P. Macfarlane, P. Slagboom, J. Jukema, 2007 .

Inflammatory mediators in atherosclerosis

C. Packard, B. Griffin, M. Caslake, 2009 .

The effect of smoking on post‐heparin lipoprotein and hepatic lipase, cholesteryl ester transfer protein and lecithin:cholesterol acyl transferase activities in human plasma

C. Packard, B. Griffin, M. Caslake, 1998, European journal of clinical investigation.

Genetic Variation in the Interleukin‐10 Gene Promoter and Risk of Coronary and Cerebrovascular Events

P. Macfarlane, A. D. de Craen, P. Slagboom, 2007, Annals of the New York Academy of Sciences.

Smoking and plasma lipoproteins in man: effects on low density lipoprotein cholesterol levels and high density lipoprotein subfraction distribution

C. Packard, B. Griffin, D. Freeman, 1993, European journal of clinical investigation.

Metabolism of HDL apolipoprotein A-I and A-II in Type 1 (insulin-dependent) diabetes mellitus

M. Taskinen, C. Packard, J. Shepherd, 1992, Diabetologia.

Are elevated circulating intercellular adhesion molecule 1 levels more strongly predictive of diabetes than vascular risk? Outcome of a prospective study in the elderly

P. Macfarlane, N. Sattar, F. T. E. Group, 2009, Diabetologia.

Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study

J. Borén, M. Taskinen, C. Packard, 2023, European heart journal.

Associations of indices of adiposity with atherogenic lipoprotein subfractions

C. Packard, N. Sattar, T. Han, 1998, International Journal of Obesity.

Lipoprotein-associated Phospholipase A2 (Lp PLA2), an inflammatory marker and novel independent risk factor in the West of Scotland Coronary Prevention Study (WOSCOPS)

G. Lowe, A. Rumley, C. Packard, 2000 .

Role of endogenous incretins in the regulation of postprandial lipoprotein metabolism.

N. Lundbom, J. Holst, J. Borén, 2022, European journal of endocrinology.

Separating the Mechanism-Based and Off-Target Actions of Cholesteryl Ester Transfer Protein Inhibitors With CETP Gene Polymorphisms

D. Lawlor, L. Smeeth, M. Pencina, 2010, Circulation.

C-reactive protein, fibrinogen, and cardiovascular disease prediction.

J. Gallacher, J. Danesh, D. Lawlor, 2012, The New England journal of medicine.

Distinct patterns of heparin affinity chromatography VLDL1 and VLDL2 subfractions in the different dyslipidaemias.

C. Packard, P. Gambert, L. Duvillard, 2008, Atherosclerosis.

Long-term follow-up of lipid-lowering trials

I. Ford, C. Packard, 2015, Current opinion in lipidology.

Exome Chip Meta-analysis Fine Maps Causal Variants and Elucidates the Genetic Architecture of Rare Coding Variants in Smoking and Alcohol Use

Dajiang J. Liu, J. Danesh, R. Marioni, 2019, Biological Psychiatry.

Interaction of chylomicron remnants and VLDLs during ultracentrifuge separation based on the Svedberg flotation rate – Authors’ response

J. Borén, M. Taskinen, C. Packard, 2020, Journal of internal medicine.

Genetic variants in the KIF6 region and coronary event reduction from statin therapy

M. Sabatine, I. Ford, C. Packard, 2010, Human Genetics.

Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease

J. Danesh, P. Deloukas, G. Abecasis, 2016, Science.

Management of hypercholesterolaemia in the patient with diabetes.

C. Packard, Olsson Ag, 2002, International journal of clinical practice. Supplement.

Letter by Packard Regarding Article, "Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial".

C. Packard, 2020, Circulation.